Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

Findings Support Development for Chronic Pain Indications

LA JOLLA, Calif., Feb. 11 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, was safe and well-tolerated in healthy male and female subjects when dosed once daily for five consecutive days.

"The successful completion of this Phase I trial demonstrating the safety and tolerability of NGX426 when dosed over multiple days provides support for pursuing a Phase II program in chronic indications," said Ev Graham, Chief Executive Officer of TorreyPines. "Combined with the positive results from our recently completed Phase I study of NGX426 in a capsaicin induced pain model, we are very encouraged about the potential for NGX426 to treat both acute and chronic pain conditions."

The Phase I double-blind, placebo-controlled trial enrolled 20 healthy male and female subjects in sequential, dose-escalating cohorts. Subjects received once-daily oral doses of either 90 mg or 150 mg of NGX426 or placebo for five consecutive days, approximating exposure under steady-state pharmacokinetic conditions. Overall, NGX426 was well-tolerated. There were no dose-limiting adverse events or discontinuations from the study and reported adverse events were generally mild and transient.

NGX426, an ester prodrug, is an oral form of tezampanel, TorreyPines most advanced product candidate. Pharmacokinetic analyses from two Phase I studies confirmed that when given to humans, NGX426 is rapidly converted to tezampanel, the active moiety. To date, six Phase II, double-blind, placebo-controlled trials have demonstrated that tezampanel, administered either subcutaneously or intravenously, was more effective than placebo in relieving pain across migraine, nocic
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... and NEW YORK , May 26, ... (ASX:NRT; NASDAQ: NVGN ), announced today that it will present ... 28, 2015 in New York City at ... Dr. Graham Kelly , Novogen Chairman and CEO, is scheduled ... a live webcast. To access the webcast, go to http://wsw.com/webcast/marcum3/nvgn ...
(Date:5/25/2015)... The 2015 Market Research Report ... professional and in-depth study on the current state ... with a focus on the Chinese situation. Major ... are Linde Industrial Gas, Basf, Air Products, Air ... Group, Longsheng Group, Juhua Group, Wandali Gas, Unid(Jiangsu) ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Knowledgent ... white paper that explores the potential of big data ... white paper was developed to help life sciences and ... leverage data to gain critical business insights. , The ... amounts of data driven by patient profiling, compliance and ...
(Date:5/21/2015)... May 21, 2015  Susan Hedstrom, Executive Director ... nonprofit organization dedicated to supporting research to advance ... announced today that FPWR has received the organization,s ... Shaulov contributed $1 million in support of ... "Our gift signifies ...
Breaking Biology Technology:Novogen to Present at the 2015 Marcum Microcap Conference 2Novogen to Present at the 2015 Marcum Microcap Conference 3Novogen to Present at the 2015 Marcum Microcap Conference 4Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 2Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 3New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2
... Jan. 2 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ... JPMorgan Healthcare Conference on Monday, January 7, at ... live webcast of the,presentation at:, http://www.metameetings.com/webcasts/jpmorgan/healthcare08 ... on 15 minutes early in order to,register and ...
... CALGARY, Jan. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech ... U.S.,National Cancer Institute (NCI) has filed a ... (FDA) for a Phase 1/2 clinical trial ... tube cancers using concurrent,systemic and intraperitoneal administration ...
... GATOS, Calif., Dec. 31 Three Palm ... that it has received 510(k) clearance,from the ... its WorkstationOne(TM),Breast Imaging Workstation. WorkstationOne is intended ... images, and was developed with,the goal of ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R) 2
(Date:5/22/2015)... CT , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... June 1st, it will be ending its promotional pricing and ... . Laurence Savin , Head of Marketing ... exclusive promotional pricing until the end of May. To get ... wocketwallet.com/invite and when we open the store on June 1, ...
(Date:5/21/2015)... 21, 2015 The Sync Project™ , ... for health, today announced a collaborative partnership with ... will center on collaboration on original research, joint course ... in the collaboration, The Sync Project and BerkleeICE are ... Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... pharmaceuticals can both prevent and treat Alzheimer,s Disease in mice. ... used for certain types of neuroimaging. "We looked at ... pathology was at an early stage, and in aged mice ... of the USC Davis School of Gerontology. "TSPO ligand reduced ...
... phosphatidylserine is a natural food supplement produced from beef, ... memory loss, it,s a popular treatment for older people ... Gil Ast and Dr. Ron Bochner of Tel Aviv ... discovered that the same supplement improves the functioning of ...
... past few decades, scientists have developed many devices that ... stents. While generally effective, each of these treatments has ... new study from MIT analyzes the potential usefulness of ... balloons and drug-releasing stents, but may pose fewer risks. ...
Cached Biology News:Drugs found to both prevent and treat Alzheimer's disease in mice 2Common food supplement fights degenerative brain disorders 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3
Raised to arginine vasopressin coupled to bovine thyroglobulin with carbodiimide ....
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Biology Products: